Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

farmedica d.o.o. ljubljana - gosti ekstrakt plodu palmeta - kapsula, mehka - gosti ekstrakt plodu palmeta 320 mg / 1 tableta - plod palmeta

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

farmedica d.o.o. ljubljana - borneol; cineol; kamfen; levomentol; menton; pinen - gastrorezistentna kapsula, mehka - borneol 5 mg / 1 kapsula  cineol2 mg / 1 kapsula  kamfen5 mg / 1 kapsula  levomentol32 mg / 1 kapsula  menton6 mg / 1 kapsula  pinen17 mg / 1 kapsula; cineol 2 mg / 1 kapsula  kamfen5 mg / 1 kapsula  levomentol32 mg / 1 kapsula  menton6 mg / 1 kapsula  pinen17 mg / 1 kapsula; kamfen 5 mg / 1 kapsula  levomentol32 mg / 1 kapsula  menton6 mg / 1 kapsula  pinen17 mg / 1 kapsula; levomentol 32 mg / 1 kapsula  menton6 mg / 1 kapsula  pinen17 mg / 1 kapsula; menton 6 mg / 1 kapsula  pinen17 mg / 1 kapsula; pinen 17 mg / 1 kapsula - druga zdravila za bolezni žolča

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

farmedica d.o.o. ljubljana - anetol; borneol; cineol; fenhon; kamfen; pinen - gastrorezistentna kapsula, mehka - anetol 4 mg / 1 kapsula  borneol10 mg / 1 kapsula  cineol3 mg / 1 kapsula  fenhon4 mg / 1 kapsula  kamfen15 mg / 1 kapsula  pinen31 mg / 1 kapsula; borneol 10 mg / 1 kapsula  cineol3 mg / 1 kapsula  fenhon4 mg / 1 kapsula  kamfen15 mg / 1 kapsula  pinen31 mg / 1 kapsula; cineol 3 mg / 1 kapsula  fenhon4 mg / 1 kapsula  kamfen15 mg / 1 kapsula  pinen31 mg / 1 kapsula; fenhon 4 mg / 1 kapsula  kamfen15 mg / 1 kapsula  pinen31 mg / 1 kapsula; kamfen 15 mg / 1 kapsula  pinen31 mg / 1 kapsula; pinen 31 mg / 1 kapsula - topila za konkremente

Europeiska unionen - slovenska - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - levkemija, limfocitna, kronična, b-celica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Europeiska unionen - slovenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Europeiska unionen - slovenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Europeiska unionen - slovenska - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - antineoplastična sredstva - rituzena je navedeno v odraslih za naslednje indikacije:ne-hodgkinova limfomi (nhl)rituzena je primerna za zdravljenje predhodno nezdravljenih bolnikov s fazo iii iv folikularni limfom v kombinaciji s kemoterapijo. rituzena monotherapy je indiciran za zdravljenje bolnikov z faza iii iv folikularni limfom, ki so kemo odporne ali so v drugi ali poznejši ponovitve po kemoterapijo. rituzena je indiciran za zdravljenje bolnikov z cd20 pozitivni razpršenih velika b celic, ki niso hodgkinova limfom v kombinaciji z chop (ciklofosfamid, doxorubicin, vincristine, prednizolon) kemoterapijo. kronično limfocitno levkemijo (cll)rituzena v kombinaciji s kemoterapijo je indiciran za zdravljenje bolnikov z predhodno nezdravljenih in relapsed/ognjevzdržni cll. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z rituzenaor bolnikov, ognjevzdržni, da prejšnji rituzena plus kemoterapijo. granulomatosis z polyangiitis in mikroskopsko polyangiitisrituzena, v kombinaciji z glucocorticoids, je primerna za indukcijo remisije pri odraslih bolnikih s hudo, aktivno granulomatosis z polyangiitis (wegener) (gpa) in mikroskopsko polyangiitis (mpa).

Europeiska unionen - slovenska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Europeiska unionen - slovenska - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - cepiva - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Slovenien - slovenska - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

dr. gustav klein gmbh & co. kg - tekoči ekstrakt cveta prave kamilice; tekoči ekstrakt korenine gozdnega korena; tekoči ekstrakt korenine golostebelnega sladkega korena; tekoči ekstrakt zeli benediktinke; tekoči ekstrakt zeli gosjega petoprstnika; tekoči ekstrakt zeli pravega pelina - peroralne kapljice, raztopina - tekoči ekstrakt cveta prave kamilice 0,2 ml / 1 ml  tekoči ekstrakt korenine gozdnega korena0,05 ml / 1 ml  tekoči ekstrakt korenine golostebelnega sladkega korena0,15 ml / 1 ml  tekoči ekstrakt zeli benediktinke0,05 ml / 1 ml  tekoči ekstrakt zeli gosjega petoprstnika0,35 ml / 1 ml  tekoči ekstrakt zeli pravega pelina0,05 ml / 1 ml; tekoči ekstrakt korenine gozdnega korena 0,05 ml / 1 ml  tekoči ekstrakt korenine golostebelnega sladkega korena0,15 ml / 1 ml  tekoči ekstrakt zeli benediktinke0,05 ml / 1 ml  tekoči ekstrakt zeli gosjega petoprstnika0,35 ml / 1 ml  tekoči ekstrakt zeli pravega pelina0,05 ml / 1 ml; tekoči ekstrakt korenine golostebelnega sladkega korena 0,15 ml / 1 ml  tekoči ekstrakt zeli benediktinke0,05 ml / 1 ml  tekoči ekstrakt zeli gosjega petoprstnika0,35 ml / 1 ml  tekoči ekstrakt zeli pravega pelina0,05 ml / 1 ml; tekoči ekstrakt zeli benediktinke 0,05 ml / 1 ml  tekoči ekstrakt zeli gosjega petoprstnika0,35 ml / 1 ml  tekoči ekstrakt zeli pravega pelina0,05 ml / 1 ml; tekoči ekstrakt zeli gosjega petoprstnika 0,35 ml / 1 ml  tekoči ekstrakt zeli pravega pelina0,05 ml / 1 ml; tekoči ekstrakt zeli pravega pelina 0,05 ml / 1 ml - razna zdravila za bolezni prebavil in presnove